Michael Lowe
Impact in
- Oncology top 2%
- Cutaneous Melanoma Detection and Management
- Cancer-related Molecular Pathways
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
- Oncology 59
- Cutaneous Melanoma Detection and Management 31
- CAR-T cell therapy research 16
- Cancer Immunotherapy and Biomarkers 7
- Polyomavirus and related diseases 5
- Cancer-related Molecular Pathways 5
- Immunology 14
- Immune Cell Function and Interaction 7
- Immunotherapy and Immune Responses 7
- Co-authors
- Khandan Keyomarsi (5 shared papers)Thaddeus W Herliczek (3 shared papers)Sarah S. Bacus (2 shared papers)Andrew F Smith (1 shared paper)Amanda Nicholson (1 shared paper)Sharon R Lewis (1 shared paper)Priscilla Alderson (1 shared paper)Xiaomei Chen (1 shared paper)
- Journals
- Annals of Surgical Oncology (22 papers)The Lancet (6 papers)The American Surgeon (4 papers)Journal of Surgical Oncology (4 papers)Journal of the American College of Surgeons (3 papers)
- Partner nations
- United StatesAustraliaUnited Kingdom
In The Last Decade
Michael Lowe
104 papers receiving 5.8k citations
Michael Lowe's Hit Papers
Peers
Comparison fields: 5 of 157
- Oncology 1.9k
- Infectious Diseases 988
- Cancer Research 606
- Applied Microbiology and Biotechnology 55
- Immunology 533
Countries citing papers authored by Michael Lowe
This map shows the geographic impact of Michael Lowe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Lowe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Lowe more than expected).
Fields of papers citing papers by Michael Lowe
This network shows the impact of papers produced by Michael Lowe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Lowe. The network helps show where Michael Lowe may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Lowe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 112 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma Hit paper breakdown → | 2023 | 581 |
| 2 | 2002 | 478 | |
| 3 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 403 |
| 4 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 381 |
| 5 | Systematic review and meta-analysis of enhanced recovery programmes in surgical patients Hit paper breakdown → | 2014 | 346 |
| 6 | 2001 | 324 | |
| 7 | 1999 | 314 | |
| 8 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 9 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 230 |
| 10 | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 211 |
| 11 | 2019 | 176 | |
| 12 | 1998 | 169 | |
| 13 | 1976 | 128 | |
| 14 | 1977 | 123 | |
| 15 | 2011 | 122 | |
| 16 | 1981 | 108 | |
| 17 | 2023 | 83 | |
| 18 | 2012 | 81 | |
| 19 | 2019 | 80 | |
| 20 | 2012 | 72 |
About Michael Lowe
Michael Lowe is a scholar working on Oncology, Immunology, Biophysics, Biochemistry and Ophthalmology, having authored 112 papers that have together received 6.0k indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (31 papers), CAR-T cell therapy research (16 papers), Melanoma and MAPK Pathways (8 papers), Immune Cell Function and Interaction (7 papers), Cancer Immunotherapy and Biomarkers (7 papers), Immunotherapy and Immune Responses (7 papers), Polyomavirus and related diseases (5 papers) and Cancer-related Molecular Pathways (5 papers). The work is most often cited by research in Oncology (1.9k citations), Infectious Diseases (988 citations), Cancer Research (606 citations), Applied Microbiology and Biotechnology (55 citations) and Immunology (533 citations). Michael Lowe has collaborated with scholars based in United States, Australia and United Kingdom. Frequent co-authors include Khandan Keyomarsi, Thaddeus W Herliczek, Sarah S. Bacus, Andrew F Smith, Amanda Nicholson, Sharon R Lewis, Priscilla Alderson, Xiaomei Chen, Donald C. Porter and Ernest Hamel. Their work appears in journals such as Annals of Surgical Oncology, The Lancet, The American Surgeon, Journal of Surgical Oncology and Journal of the American College of Surgeons.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.